GlassScriptPhysician profile
Leyland A Thomas
NPI 1922068121
$1,041.37
in general payments reported to CMS, 2019-2025
20 companies · $92.00 in 2025
The $92.00 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $108 · 2021: $129 · 2022: $204 · 2023: $113 · 2024: $151 · 2025: $92.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $356.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $171.47 | 2019-2021 | |
| Abbvie INC. | $143.64 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $122.86 | 2022-2023 | Uzedy, Austedo Xr |
| Alkermes, INC. | $97.10 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $72.72 | 2022-2023 | Rexulti |
| Exact Sciences Corporation | $60.55 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $50.89 | 2019 | |
| Novo Nordisk INC | $44.20 | 2022-2024 | Ozempic, Rybelsus |
| Amgen INC. | $40.18 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $36.92 | 2019-2020 | |
| Pfizer INC. | $30.43 | 2019-2025 | |
| Lilly USA, LLC | $26.13 | 2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.06 | 2020-2021 | |
| Amarin Pharma, INC. | $23.03 | 2020 | |
| Hologic Sales and Service, LLC | $21.59 | 2024 | Aptima, Thinprep 2000 Processor, Third Wave |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $19.38 | 2022 | |
| Indivior INC. | $16.20 | 2019 | |
| Corium, LLC | $16.18 | 2021 | |
| Mdd US Operations, LLC | $11.93 | 2019 | |
| Genentech USA, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leyland Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.